Compare TTSH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTSH | DCTH |
|---|---|---|
| Founded | 1985 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.3M | 350.7M |
| IPO Year | N/A | N/A |
| Metric | TTSH | DCTH |
|---|---|---|
| Price | $3.58 | $10.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | ★ 848.3K | 527.6K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $338,787,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.69 |
| Revenue Next Year | N/A | $39.22 |
| P/E Ratio | ★ N/A | $299.08 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $3.56 | $8.12 |
| 52 Week High | $7.75 | $18.23 |
| Indicator | TTSH | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 13.70 | 58.13 |
| Support Level | $3.56 | $9.92 |
| Resistance Level | $4.35 | $10.40 |
| Average True Range (ATR) | 0.49 | 0.41 |
| MACD | -0.30 | 0.02 |
| Stochastic Oscillator | 1.41 | 57.55 |
Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.